RET-positive Ongoing Clinical Trials

Clinical trials looking at possible next-generation RET inhibitors in all solid tumors with RET gene abnormalities:

These clinical trials are looking at the safety and efficacy of novel agents developed to overcome resistance mechanisms seen in patients who have progressed on the ‘first generation’ RET-targeting tyrosine kinase inhibitors (TKIs) Selpercatinib (Retevmo) and Pralsetinib (Gavreto).

ClinicalTrials.gov ID Title Phase Locations Sponsor Date Opened Contact
NCT05443126 A Study of EP0031-101 in Patients With Advanced RET-altered Malignancies I/II

Los Angeles California, Cleveland Ohio, Portland Oregon, Houston Texas

Ellipses Pharma Jul-22 Liz@ellipses.life
NCT05653869 A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions I

Shanghai China

Applied Pharmaceutical Science, Inc. Dec-22 liuxueying@apspharm.com, zhongjun@apspharm.com

Clinical trials looking at first-generation RET inhibitors in all RET-positive solid tumors:

ClinicalTrials.gov ID Title Phase Locations Sponsor Date Opened Contact
NCT03037385 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) I/II 79 locations worldwide Blueprint Medicines Corporation Mar-17 studydirector@blueprintmedicines.com
NCT03157128 Phase 1/2 Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) I/II 84 locations world wide Loxo Oncology May-17 clinicaltrials@loxooncology.com
NCT03157128 Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study II 153 locations world wide Hoffmann-La Roche October-20 Global-Roche-Genentech-Trials@gene.com

Clinical trials comparing first-generation RET inhibitors to standard-of-care chemotherapy in RET Fusion-positive NSCLC:

ClinicalTrials.gov ID Title Phase Locations Sponsor Date Opened Contact
NCT04194944 A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) III 216 Locations world wide Eli Lilly Feb-20 ClinicalTrials.gov@lilly.com
NCT04222972 AcceleRET Lung Study of Pralsetinib for 1L RET Fusionpositive, Metastatic NSCLC III 58 Locations world wide Blueprint Medicines Corporation Jan-20 medinfo@blueprintmedicines.com

Clinical trials looking at first-generation RET inhibitors for RET-altered Thyroid Cancers:

ClinicalTrials.gov identifier Number Title Phase Locations Sponsor Date Opened Contact
NCT04211337 A Study of Selpercatinib (LY3527723) in Participants with RET-Mutant Thyroid Cancer (LIBRETTO-531) III 156 study locations worldwide Eli Lilly Dec-19 ClinicalTrials.gov@lilly.com
NCT04759911 Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer II MD Anderson MD Anderson Not yet recruiting mzafereo@mdanderson.org
NCT04760288 A study of Pralsetinib Versus Standard of Care for Treatment of RET-Mutated Medullary Thyroid Cancer III Not yet recruiting Hoffmann-La Roche Not yet recruiting global-roche-genentech-trials@gene.com